Clinical Trials Logo

Urinary Bladder Neoplasms clinical trials

View clinical trials related to Urinary Bladder Neoplasms.

Filter by:

NCT ID: NCT06119724 Active, not recruiting - Bladder Cancer Clinical Trials

Bipolar Enbloc Versus Thulium-Yag Enbloc Resection of Bladder Tumors

TURBT-Enbloc
Start date: June 11, 2023
Phase: N/A
Study type: Interventional

Prospective controlled study randomized comparing bipolar enbloc versus thulium enbloc for bladder tumours

NCT ID: NCT06115434 Recruiting - Clinical trials for Urinary Bladder Cancer

Comparing Operative, Postoperative and Quality of Life of Patients After Salvage and Radical Cystectomy

Start date: January 30, 2015
Phase:
Study type: Observational [Patient Registry]

To compare operative difficulties, type of urinary diversion, intraoperative & postoperative complications and quality of life in patients underwent radical cystectomy and those after salvage cystectomy.

NCT ID: NCT06111235 Recruiting - Bladder Cancer Clinical Trials

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Start date: December 14, 2023
Phase: Phase 3
Study type: Interventional

This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by observation for the treatment of participants with IR-NMIBC.

NCT ID: NCT06109857 Recruiting - Hematuria Clinical Trials

Bladder Bank (a Prospective Banking Study)

Start date: July 6, 2022
Phase:
Study type: Observational

This study collects blood and urine samples from patients with bladder cancer to support the development of tests for early detection of bladder cancer.

NCT ID: NCT06108492 Recruiting - Clinical trials for High-risk Non-muscle Invasive Bladder Cancer

A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Start date: November 28, 2023
Phase: Phase 1
Study type: Interventional

This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-2005 for Intravesical perfusion in patients with high-risk non-muscle invasive bladder cancer.

NCT ID: NCT06100653 Recruiting - Clinical trials for Non-muscular Invasive Bladder Cancer

BCG for Therapeutic Use Phase I Clinical Trial

Start date: November 22, 2023
Phase: Phase 1
Study type: Interventional

This clinical study adopted a single-arm, open, single-centertrial design. The purpose of this study was to evaluate the safety and tolerability, PK characteristics, shedding and immune response characteristics of BCG for therapeutic use developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. in patients aged 18 and over after transethral resection of non-muscular invasive bladder cancer.

NCT ID: NCT06092450 Recruiting - Bladder Cancer Clinical Trials

Deep Learning Radiomics Model for Predicting Post-cystectomy Outcome in Muscle Invasive Bladder Cancer

Start date: August 1, 2023
Phase:
Study type: Observational

Muscle invasive bladder cancer (MIBC) has a poor prognosis even after radical cystectomy. Postoperative survival stratification based on radiomics and deep learning may be useful for treatment decisions to improve prognosis. This study was aimed to develop and validate a deep learning radiomics model based on preoperative enhanced CT to predict postoperative survival in MIBC.

NCT ID: NCT06091124 Recruiting - Bladder Cancer Clinical Trials

Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma

RJBLC-NEBC001
Start date: November 16, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to learn about the efficacy and safety of neoadjuvant adebrelimab plus etoposide and cisplatin in patients with neuroendocrine bladder carcinoma. The main questions it aims to answer are: - The pathologic complete response rate at radical cystectomy - Safety and tolerability of combination therapy Participants will be treated with a combination therapy of adebrelimab, etoposide, and cisplatin before radical cystectomy, with a maximum of 4 cycles.

NCT ID: NCT06090318 Withdrawn - Gastric Cancer Clinical Trials

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Start date: May 19, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, single-arm, Phase 1b/2 study designed to evaluate the safety, tolerability, and preliminary efficacy of milademetan in combination with atezolizumab in patients with advanced solid tumors with confirmed homozygous CDKN2A loss and WT TP53 who have progressed on or are refractory to prior PD-1/PD-L1 inhibitor therapy and who, in the opinion of the Investigator, are unlikely to tolerate or derive clinically meaningful benefit from other therapy. This study will determine the recommended dose of milademetan when given in combination with atezolizumab (the combination RP2D) using a dose de-escalation safety assessment cohort (Phase 1b). Following identification of the combination RP2D, the safety profile and preliminary anti-tumor activity of the combination RP2D will be evaluated in a larger population in a dose expansion cohort (Phase 2).

NCT ID: NCT06087016 Recruiting - Clinical trials for Urinary Bladder Tumour

Urinary Markers by SpectrosCopy: Diagnostic Aid in oncologY - Application to Urological Cancers

MUSCADE
Start date: March 6, 2023
Phase:
Study type: Observational

This study aims to evaluate the performance of vibrational spectroscopy (Infrared and Raman spectroscopy techniques) in bladder cancer diagnosis using urine samples.